Patient Selection for Upfront Immunotherapy in NSCLC – OncLive
OncLive |
Patient Selection for Upfront Immunotherapy in NSCLC
OncLive Everett Vokes, MD: You mentioned a number of trials that are very information to this. Naiyer, I wonder if you could just go over those a little bit more in detail? When should pembrolizumab, alone, be used? There's an alternative of combining … |
